Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021프라이밍, 부스팅 및 하이브리드 면역에 따른 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 항체 매개 면역원성: 이스라엘 의료 종사자 집단의 11개월 추적 관찰에서 얻은 통찰력, 2020년 12월-2021년 10월Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] acute respiratory syndrome Against age all age group all age groups anti-S Antibody titer Breakthrough infection circulating Cohort comparable coronavirus coronavirus 2 coronavirus disease COVID-19 decrease described dose doses geometric mean concentration GMC HCW HCWs healthcare worker highlight hybrid IgG IgG level IgG levels IgG titer Immunity immunogenicity Immunoglobulin individual infected individual infected individuals Infection initial insight Israel Month participant PCR polymerase chain proportion Protective Quantitative re-infected Reinfection remained respiratory reversed S1/S2 SARS-CoV-2 subsequent tested timepoint uninfected vaccination Vaccine vaccine immunogenicity Vaccines waned worker [DOI] 10.1093/cid/ciac212 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in ChileArticle Published on 2022-08-242022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, [키워드] activate acute respiratory syndrome Adverse reaction age analyzed binding domain blood sample cellular characterized Chilean circulating clinical trial CoronaVac coronavirus coronavirus 2 coronavirus disease COVID-19 dose effective vaccine enrolled healthy humoral IFN-γ IgG immunogenicity Immunoglobulin inactivated incidence induce injection interferon-γ Local measure Mild neutralizing antibody neutralizing capacity Pain peptide Phase 3 phase 3 clinical trial Placebo pool profiles promote Randomly RBD Registered reported respiratory Safe Safety SARS-CoV-2 SARS-CoV-2 antigens second dose secretion separated severe adverse event significant increase subset T cells T-cell Response the vaccine Vaccine Vaccines Volunteer volunteers was performed [DOI] 10.1093/cid/ciab823 PMC 바로가기
Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational StudyPost-mRNA 예방접종 후 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 면역글로불린 G(IgG) 농도 및 HIV(인간면역결핍바이러스)에 의한 대리바이러스 중화시험 반응의 차이 백신의 상태 및 유형: 일치된 사례-대조군 관찰 공부하다Observational Study Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome BNT162b2 vaccine CD4+ T-cell coronavirus coronavirus 2 COVID-19 difference HIV Human Human immunodeficiency virus IgG immune immune response Immunoglobulin Immunoglobulin G Matched mRNA vaccination PLWH respiratory response SARS-CoV-2 status surrogate Test Type vaccination vaccine dose virus neutralization test [DOI] 10.1093/cid/ciab1009 PMC 바로가기 [Article Type] Observational Study
IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in KarachiKarachi의 두 시점에서 무증상 헌혈자의 SARS-CoV-2에 대한 IgG 항체Article Published on 2022-08-242022-09-11 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, [키워드] 95% CI ABO age antibody Antigen Asymptomatic blood donor Blood donors Blood Group Blood groups Cohort COVID-19 COVID-19 infections Donor donors enrolled Enrollment exposure to frequencies Frequency group groups healthy healthy blood donor IgG IgG antibodies IgG antibody IgG response IgG responses incidence of COVID-19 individual individuals Infection Karachi male material no significant difference not differ pandemic protective immunity Proteins provide RBD reactivity Receptor binding domain reported SARS-CoV-2 SARS-CoV-2 PCR testing seropositive Seropositivity Seroprevalence significant difference spike subject Symptom university were measured [DOI] 10.1371/journal.pone.0271259 PMC 바로가기 [Article Type] Article
Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells in Whole Blood전혈에서 중증 급성 호흡기 증후군 코로나바이러스 2-특이적 T 세포 분석을 위한 신속한 사이토카인 방출 분석Article Published on 2022-08-242022-09-11 Journal: The Journal of Infectious Diseases [Category] SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed anti-receptor-binding domain antibody Blood samples characteristic clinical complicate Complication controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine cytokine Cytokine release assay diagnosed Diagnosis Diagnostic accuracy Donor EudraCT evaluated exhibited high accuracy IgG IgG levels Immunoglobulin Immunoglobulin G induction Infection interferon interferon γ memory memory response nucleocapsid Patient peptide peptides plasma Previous studies protocol Rapid receiver receiver operating characteristic Region Release remained respiratory SARS-CoV-2 seropositive serum severe acute respiratory syndrome Coronavirus spike stimulated study participant supernatant T cells T-cell T-cell immunity Trial vaccine doses waned Whole blood [DOI] 10.1093/infdis/jiac005 PMC 바로가기 [Article Type] Article
Long-Term Accuracy of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay and Its Application in Household Investigation중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 인터페론-γ 방출 분석의 장기 정확도 및 가정 조사에서의 적용Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, 치료기술, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody responses antigen-specific T cell application applied Blood Blood donors cell-mediated immune cell-mediated immune response clinical assessment collected Contact convalescent coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 declined detect diagnostic epidemiological Epidemiological investigation evaluated exhibiting healthy blood donors household Households IFN-γ IgG IGRA Immunocompromised Immunocompromised patients index case index cases interferon investigation lithium Lithium heparin mitogen peptide peptide pool positive Post-infection Release remained respiratory responses robust SARS-CoV-2 SARS-CoV-2 antigen sensitivity Sensitivity and specificity severe acute respiratory syndrome Coronavirus stimulated T cells T-cell T-cell Response tested Vaccines variant Whole blood whole blood assay [DOI] 10.1093/cid/ciac045 PMC 바로가기 [Article Type] Article
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA VaccineArticle Published on 2022-08-232022-11-16 Journal: ACS Nano [Category] COVID19(2023년), SARS, 치료기술, [키워드] antibodies antibody association biomolecular coronas Blood BNT162b2 cell interaction cell interactions clinical impact clinically correlated COVID-19 dose elevated environmental exposure Ex vivo glycol Human human blood assay identify IgG IgM immunoglobulins increase in Lipid LNP Moderna mRNA mRNA vaccination mRNA vaccine mRNA-1273 nanoparticle Neutralizing antibody response overcome particle−immune cell interactions. PEGylated lipid nanoparticle Pfizer-BioNTech phagocyte plasma receiving SARS-CoV-2 SARS-CoV-2 vaccine significant increase significantly systemic reactogenicity the SARS-CoV-2 vaccination Vaccine [DOI] 10.1021/acsnano.2c04543 PMC 바로가기
Saliva-based SARS-CoV-2 serology using at-home collection kits returned via mail우편을 통해 반환된 집에서 수집 키트를 사용하는 타액 기반 SARS-CoV-2 혈청학Article Published on 2022-08-182022-09-11 Journal: Scientific Reports [Category] Coronavirus, SARS, 진단, 치료기술, [키워드] analyzed comparable Compliance coronavirus diagnostic diagnostic testing Effect Endemic Factors framework full-length spike protein identify IgG Laboratory longitudinal mail MONITOR multiplex N antigen Patient PCR test PCR testing performed Prospective Study provide reactivity recruited refrigeration returned Saliva salivary SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens sensitivity Sensitivity and specificity Seroconversion serologic testing serology serum specificity specimen Spike protein threshold thresholds Vaccine [DOI] 10.1038/s41598-022-17057-7 PMC 바로가기 [Article Type] Article
Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort인구 기반 코호트에서 SARS-CoV-2 감염 후 뚜렷한 궤적을 가진 이종 체액성 및 세포성 면역 반응Article Published on 2022-08-182022-09-11 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, 치료법, [키워드] Analysis anti-N IgG anti-S responses antibody Antibody responses Cellular immune response cellular immunity cellular response characterized clinical factors Cluster analyses Delta detectable develop Diagnosis FIVE heterogeneity humoral humoral and cellular immunity Humoral and cellular responses identify IgA IgG immune Immunity individual infected individuals Infection maintain membrane Neutralizing activity neutralizing antibody omicron Omicron variants Participants population-based cohort required responses S proteins SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected individual T cell T cell response T cell responses T cells trajectory variant [DOI] 10.1038/s41467-022-32573-w PMC 바로가기 [Article Type] Article
Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine dosesArticle Published on 2022-08-172022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] adaptive Administered antibody Asymptomatic BNT162b2 Breakthrough infection breakthrough infections cellular Cohort COVID-19 COVID-19 pandemic declined determine dose effective Follow-up healthcare humoral humoral immune response Hybrid immunity IgG immune immune response Immunity Inclusion increase in individual knowledge Longitudinal assessment Mild mRNA vaccine mRNA-1273 naïve naïve individual naïve individuals neutralization neutralizing antibody peak level Prevent reached reported SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2-specific T cells second dose T cell T cells third dose triggered vaccination Vaccine Viral antigen [DOI] 10.3389/fimmu.2022.981350 PMC 바로가기